i•FISH^® Products for Human Specimens

Cytelligen's patented technology integrates FISH and immunofluorescence staining with any tumor markers of customers' choice to identify the targeted, non-hematologic aneuploid circulating rare cells including CTCs and CTECs. 

iFISH is performed on cells fixed on the Cytelligen’s specially coated CTC slide which prevents any peeling and minimizes background interference. The finished slides are capable for long term storage. Target cells identified by iFISH are suitable for quantification and single cell analysis. The most distinct advantage of Cytelligen's iFISH is its exceedingly high sensitivity and exceptionally unique specificity compared to immunofluorescence staining alone. Identified CTCs or CTECs cells are classified into diverse subtypes upon cell size, tumor marker protein expression and aneuploidy of chromosomes. Individual iFISH cells fixed on the coated slide can be respectively extracted utilizing a Cytelligen’s non-laser microscopic single cell manipulator (NMSCM) for downstream NGS analysis, etc.   

iFISH (NC) can effectively identify, characterize and subcategorize various necrotic and viable CTCs and CTECs. Each subtype of CTCs and CTECs correlates with distinct significance in anti-cancer drug development, translational research and clinical practice with respect to risk stratification, rapid evaluation of therapeutic effects, monitoring of treatment-resistance, and detection of post-therapeutic minimal residual disease (MRD).

EC: endothelial cell; NCS: necrotic cell staining.

Part of available antibodies against tumor markers including EpCAM, Vimentin, HER2, PD-L1, CK18, PSMA, AFP, CA19-9, GPC3, Mesothelin, DR4, EGFR, CD44v6, CD133, etc. Customization of antibody against any tumor marker is feasible. 

Besides CEP8, ALK-iFISH (Lin 2018, Diagnostics 8, 26), or customized integration of different FISH probes into the iFISH platform is also available.